EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Phenotype-Oriented Characterization of NSC828786 Identifies Convergent HPN-AMACR-Associated Transcriptomic Signatures in Prostate Adenocarcinoma and Broad-Spectrum Antiproliferative Activity

Ya-Ting Wen, Rosario Trijuliamos Manalu iD, Han-Lin Hsu, Yu-Cheng Kuo, Ruey-Shyang Soong, Feng-Cheng Liu iD, Maryam Rachmawati Sumitra, Sheng-Liang Huang, Shih-Yu Lee iD, Sung-Ling Tang iD, I-Chuan Yen, Hong-Jaan Wang iD und 3 weitere

Cells · 22.07.2026 · 15 (14) · 1314

DOI: 10.3390/cells15141314 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 22.07.2026. Verfasst von Ya-Ting Wen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Wan Fang Hospital, Taipei Medical University, Taipei 11681, Taiwan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Adenocarcinoma, Transcriptome, Racemases and Epimerases. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Taipei Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer remains a major cause of cancer-related mortality, and new therapeutic strategies are needed for advanced disease. Niclosamide and related salicylanilide compounds have emerged as multitarget anticancer agents, but the molecular contexts associated with their activity remain incompletely understood. Here, we applied a phenotype-oriented integrative framework to characterize the molecular context and phenotypic activity of NSC828786, a niclosamide-like salicylanilide derivative. Cross-cohort transcriptomic analyses identified AMACR (alpha-methylacyl-CoA racemase) and HPN (hepsin) as consistently upregulated genes in independent prostate adenocarcinoma cohorts. NCI-60 profiling demonstrated broad-spectrum low-micromolar antiproliferative activity, including AR-negative prostate cancer and breast cancer cell lines spanning multiple receptor subtypes; however, quantitative ranking did not support preferential receptor subtype selectivity. CellMiner COMPARE analysis showed no significant correlation between baseline AMACR or HPN expression and NSC828786 sensitivity. Structure-based analyses supported computational compatibility of NSC828786 with predicted HPN- and AMACR-associated binding regions, while zebrafish assays showed no overt developmental abnormalities at concentrations ≤ 5 μM. These findings identify NSC828786 as a phenotypically active salicylanilide derivative and position HPN and AMACR as exploratory candidate molecular associations warranting further mechanistic and target engagement studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsAdenocarcinomaTranscriptomeRacemases and EpimerasesSalicylanilidesAntineoplastic AgentsNiclosamideMaleHumansCell ProliferationCell Line, TumorAnimalsPhenotypeZebrafishGene Expression Regulation, NeoplasticGene Expression Profiling

Stichwörter der Autor:innen

AMACRHPNNSC828786niclosamide-like salicylanilidephenotype-oriented analysisprostate adenocarcinoma

Substanzen

alpha-methylacyl-CoA racemaseRacemases and EpimerasesSalicylanilidesAntineoplastic AgentsNiclosamide

Autor:innen und Institutionen

  • Department of Neurosurgery, Wan Fang Hospital, Taipei Medical University, Taipei 11681, Taiwan.
  • Division of Neurosurgery, Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
  • Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
  • Faculty of Pharmacy, National Institute of Science and Technology, Jakarta 12630, Indonesia.
  • Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
  • Department of Pharmacology, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.

ORCID-Profile: Rosario Trijuliamos Manalu, Feng-Cheng Liu, Shih-Yu Lee, Sung-Ling Tang, Hong-Jaan Wang, Bashir Lawal, Alexander T H Wu, Hsu-Shan Huang

Förderung

  • National Science and Technology Council
  • Taipei Medical University

Zitieren

APA

Wen, Y. T., Manalu, R. T., Hsu, H. L., Kuo, Y. C., Soong, R. S., Liu, F. C., Sumitra, M. R., Huang, S. L., Lee, S. Y., Tang, S. L., Yen, I. C., Wang, H. J., Lawal, B., Wu, A. T. H., & Huang, H. S. (2026). Phenotype-Oriented Characterization of NSC828786 Identifies Convergent HPN-AMACR-Associated Transcriptomic Signatures in Prostate Adenocarcinoma and Broad-Spectrum Antiproliferative Activity. Cells, 15(14), 1314. https://doi.org/10.3390/cells15141314

Vancouver

Wen YT, Manalu RT, Hsu HL, Kuo YC, Soong RS, Liu FC, et al. Phenotype-Oriented Characterization of NSC828786 Identifies Convergent HPN-AMACR-Associated Transcriptomic Signatures in Prostate Adenocarcinoma and Broad-Spectrum Antiproliferative Activity. Cells. 2026;15(14):1314. doi:10.3390/cells15141314

BibTeX
@article{Wen2026,
  author = {Wen, Ya-Ting and Manalu, Rosario Trijuliamos and Hsu, Han-Lin and Kuo, Yu-Cheng and Soong, Ruey-Shyang and Liu, Feng-Cheng and Sumitra, Maryam Rachmawati and Huang, Sheng-Liang and Lee, Shih-Yu and Tang, Sung-Ling and Yen, I-Chuan and Wang, Hong-Jaan and Lawal, Bashir and Wu, Alexander T H and Huang, Hsu-Shan},
  title = {Phenotype-Oriented Characterization of NSC828786 Identifies Convergent HPN-AMACR-Associated Transcriptomic Signatures in Prostate Adenocarcinoma and Broad-Spectrum Antiproliferative Activity},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {14},
  pages = {1314},
  doi = {10.3390/cells15141314}
}
Kostenlos starten →